Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nihon Trim Co., Ltd. ( (JP:6788) ) just unveiled an announcement.
Nihon Trim has nominated Takafumi Shimizu as a part-time director, leveraging his long-standing connection with the company and his current role as representative director and president of its consolidated subsidiary, StemCell Institute Inc. The appointment, to be decided at the late June 2026 shareholders’ meeting, aligns the parent with key expertise in medical and overseas businesses through a leader already active in the group’s growth segment.
Management highlights Shimizu’s background in business strategy, overseas expansion, and corporate planning at Nihon Trim, combined with his top management experience at StemCell Institute. By adding him to the board, Nihon Trim aims to strengthen groupwide governance and ensure more transparent, comprehensive decision-making that reflects both its core operations and its expanding medical business interests.
The most recent analyst rating on (JP:6788) stock is a Buy with a Yen5618.00 price target. To see the full list of analyst forecasts on Nihon Trim Co., Ltd. stock, see the JP:6788 Stock Forecast page.
More about Nihon Trim Co., Ltd.
Nihon Trim Co., Ltd., listed on the Tokyo Stock Exchange Prime Market under code 6788, operates in the healthcare-related sector and oversees a group that includes medical businesses. Its portfolio includes a majority stake in StemCell Institute Inc., a consolidated subsidiary focused on medical and stem cell-related services and listed on the TSE Growth Market, underscoring the group’s strategic emphasis on advanced medical fields.
YTD Price Performance: -9.44%
Average Trading Volume: 17,764
Technical Sentiment Signal: Buy
Current Market Cap: Yen35.42B
For a thorough assessment of 6788 stock, go to TipRanks’ Stock Analysis page.